Cart
sales@molnova.com
VMY-1-103
CAS No. 1209002-43-6
VMY-1-103( VMY 1-103 )
Catalog No. M10779 CAS No. 1209002-43-6
A novel dansylated analog of purvalanol B, and a CDK inhibitor that inhibits cell cycle progression and proliferation in prostate and breast cancer cells more effectively than purvalanol B.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 5MG | 873 | Get Quote |
|
| 50MG | 1782 | Get Quote |
|
| 100MG | 2250 | Get Quote |
|
| 200MG | Get Quote | Get Quote |
|
| 500MG | Get Quote | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NameVMY-1-103
-
NoteResearch use only, not for human use.
-
Brief DescriptionA novel dansylated analog of purvalanol B, and a CDK inhibitor that inhibits cell cycle progression and proliferation in prostate and breast cancer cells more effectively than purvalanol B.
-
DescriptionA novel dansylated analog of purvalanol B, and a CDK inhibitor that inhibits cell cycle progression and proliferation in prostate and breast cancer cells more effectively than purvalanol B; increases the sub G(1) fraction of apoptotic cells, induces PARP and caspase-3 cleavage and increases the levels of the death receptors DR4 and DR5, Bax and Bad.
-
In Vitro——
-
In Vivo——
-
SynonymsVMY 1-103
-
PathwayAngiogenesis
-
TargetCDK
-
RecptorCDK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1209002-43-6
-
Formula Weight708.27
-
Molecular FormulaC34H42ClN9O4S
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=C(NCCNS(=O)(C1=C2C=CC=C(N(C)C)C2=CC=C1)=O)C3=CC=C(NC4=C5N=CN(C(C)C)C5=NC(N[C@H](C(C)C)CO)=N4)C=C3Cl
-
Chemical Name2-Chloro-N-[2-[[[5-(dimethylamino)-1-naphthalenyl]sulfonyl]amino]ethyl]-4-[[2-[[(1R)-1-(hydroxymethyl)-2-methylpropyl]amino]-9-(1-methylethyl)-9H-purin-6-yl]amino]benzamide
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Ringer L, et al. Cancer Biol Ther. 2011 Nov 1;12(9):818-26.
2. Sirajuddin P, et al. Cell Cycle. 2012 Oct 15;11(20):3801-9.
3. Waye S, et al. Aging (Albany NY). 2015 Oct;7(10):854-68.
molnova catalog
related products
-
MSC-2530818
MSC-2530818 (MSC 2530818, MSC2530818) is a potent, selective, and orally bioavailable CDK8 inhibitor with IC50 of 2.6 nM.
-
XY028-140
XY028-140 is a selective CDK4/CDK6 degrade and inhibits both CDK4/6 expression and activity in cancer cells. XY028-140 is a PROTAC connected by ligands for Cereblon and CDK.
-
Ro-3306
Ro-3306 is a potent, selective, ATP-competitive CDK1 inhibitor with Ki of 35 nM against CDK1/cyclin B1, 10-fold selectivity relative to CDK2/cyclin E and >50-fold relative to CDK4/cyclin D.
